AVH 2.37% $2.47 avita medical inc.

Ann: Pivotal Soft Tissue Trial Receives US FDA IDE Approval, page-36

  1. 208 Posts.
    lightbulb Created with Sketch. 129
    The revenues are growing by leaps and bounds, if one looks at revenue growth YoY, QoQ without BARDA revenue and just says okay the taking to market of ReCell is growing at an excellent pace. It is what it is using a company I despise but TSLA is no where worth what it is/has ever traded at on the day, but, its because of future and growth rate. Just relax. I knew there was a reason why I didn't read this board anymore, now its all coming back to me, could be a beautiful day sun shining with a slight breeze you cats would say but it could be 2 degrees warmer/cooler
 
watchlist Created with Sketch. Add AVH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.